title: Combination of laser photocoagulation and intravitreal bevacizumab (Avastin) for aggressive zone I retinopathy of prematurity.
abstract: BACKGROUND
  This report describes the use of combined laser photocoagulation and intravitreal bevacizumab administration for aggressive zone I retinopathy of prematurity (ROP).
  
  
  METHODS
  A male patient, born at 25 weeks gestation with a birth weight of 884 g, received indirect laser photocoagulation and a 0.75 mg intravitreal bevacizumab injection to each eye for aggressive stage 3 zone I ROP. Structural outcomes were evaluated 3 months after treatment.
  
  
  RESULTS
  At 3-month follow-up, treatment had resulted in ROP regression, prompt resolution of plus signs and neovascular proliferation in both eyes, and no signs of systemic or ocular adverse events.
  
  
  CONCLUSIONS
  The combination of indirect laser photocoagulation and intravitreal bevacizumab injection was well tolerated and induced prompt regression of aggressive zone I ROP.
authors: The Institute of Vision Research, Department of Ophthalmology,Yonsei University College of Medicine, Seoul, South Korea.
authors: Eun Jee
authors: EJ
authors: Chung
authors: Ji Hyun
authors: JH
authors: Kim
authors: Hyun Seok
authors: HS
authors: Ahn
authors: Hyoung Jun
authors: HJ
authors: Koh
mesh_terms: D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D003131:Combined Modality Therapy; D005500:Follow-Up Studies; D005865:Gestational Age; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D007267:Injections; D017075:Laser Coagulation; D008297:Male; D012178:Retinopathy of Prematurity / Q000188:drug therapy* / Q000601:surgery*; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors; D014822:Vitreous Body
chemical_list: D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab
references: J AAPOS. 1999 Feb;3(1):26-32
references: 10071898
references: Arch Ophthalmol. 2000 May;118(5):645-9
references: 10815156
references: N Engl J Med. 1994 Dec 1;331(22):1480-7
references: 7526212
references: Arch Ophthalmol. 1996 Oct;114(10 ):1219-28
references: 8859081
references: Retina. 2006 Sep;26(7 Suppl):S11-5
references: 16946670
references: Am J Ophthalmol. 2006 Jul;142(1):162-4
references: 16815270
references: Lab Invest. 1996 Jan;74(1):68-77
references: 8569199
references: Proc Natl Acad Sci U S A. 1995 Jan 31;92(3):905-9
references: 7846076
references: Clin Exp Ophthalmol. 2000 Feb;28(1):48-52
references: 11345346
references: J AAPOS. 2000 Dec;4(6):373-6
references: 11124674
references: Indian J Ophthalmol. 2007 Jan-Feb;55(1):75-6
references: 17189897
references: Retina. 2006 Mar;26(3):262-9
references: 16508424
references: Ann Pharmacother. 2007 Apr;41(4):614-25
references: 17355998
references: Ophthalmic Surg Lasers Imaging. 2007 May-Jun;38(3):233-7
references: 17552391
references: Retina. 2006 Oct;26(8):871-6
references: 17031285
references: J Neurosci. 2000 Sep 15;20(18):6781-8
references: 10995821
references: Am J Pathol. 1997 Jul;151(1):281-91
references: 9212753
references: Arch Ophthalmol. 2003 Dec;121(12 ):1684-94
references: 14662586
references: Br J Ophthalmol. 2006 Nov;90(11):1344-9
references: 16854824
references: Acta Ophthalmol Scand. 2003 Dec;81(6):614-6
references: 14641264
references: Arch Ophthalmol. 1990 Feb;108(2):195-204
references: 2405827
references: Ophthalmology. 2006 Oct;113(10):1695.e1-15
references: 17011951
references: Retina. 2006 Mar;26(3):257-61
references: 16508423
references: Am J Ophthalmol. 2006 Jul;142(1):46-59
references: 16815250